AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02990819 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Apha/beta T and CD19+ cell depletion using CliniMACS device
Description: Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
Study NCT03337529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 200 mg Vitamin C will be given on daily basis for 8 weeks
Study NCT03337529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg placebo will be given on daily basis for 8 weeks
Study NCT02958969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
Study NCT03122418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Fitness Device
Description: Subjects will be given a personal fitness device to use to encourage exercise routinely. The impact this has on the individual perception of their quality of life will be the primary outcome for this study
Study NCT00887497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioembolization
Description: Angioembolization
Study NCT01371344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus granules
Description: oral
Study NCT00885859 — intervention group
Intervention type: DEVICE
Intervention: TENStemeco Schwa Medico [Transcutaneous Electrical Nerve Stimulation (TENS)]
Description: Patients are instructed how to use the TENS device during the two weeks at home.Self-adhesive reusable electrodes are used to deliver the electrical stimulation. The frequency is 100 Hz, pulse duration 250 μ sec. Stimulus intensity is strong but not unpleasant. The TENS electrodes are attached proximally and distally around the maximum pain point/area. Patients use TENS 4 times daily (30 minutes each time).
Study NCT03571347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Help Plus
Description: 5-session psychosocial intervention
Study NCT03571347 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Treatment As Usual
Description: Routine social support and/or care, and information about freely available mental health services, social services, NGOs, and community networks providing support to asylum seekers and refugees
Study NCT02686359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sample
Study NCT02686359 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sample
Study NCT01799785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise for 8 weeks (3 times per week, 30-60 minutes each session)
Study NCT01799785 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Study NCT02160834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B-MOBILE Smartphone-Based Intervention (3-min break)
Description: Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time.
Study NCT02160834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B-MOBILE Smartphone-Based Intervention (6-min break)
Description: Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time.
Study NCT00666991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticulate paclitaxel
Description: This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
Study NCT01371344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus capsules
Description: oral
Study NCT00368537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ampicillin-sulbactam
Description: Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs or Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs.~A glycopeptide antibiotic (either vancomycin 1 g IV every 12 hrs or teicoplanin IV loading dose of 400 mg the first day followed by a maintenance dose of 200 mg daily) may be added to the aminopenicillin/betalactamase inhibitor regimen if infection with methicillin-resistant staphylococcus aureus (MRSA) is suspected or confirmed within the first 72 hrs of enrollment. If culture results fail to show a resistant organism, use of the glycopeptide may be discontinued.
Study NCT03458507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Switch of nocturnal NIV interface
Description: 1. test the alternative interfaces (either a nasal mask for the patient used to oronasal mask or inversely an oronasal mask if the usual mask is nasal) during a one-hour diurnal NIV session. SpO2 (polygraphy), PtcCO2 will be monitored continuously during this diurnal session. Patients will use their usual NIV device prescribed at home. NIV settings will be adapted if needed.~2. Interface switch~3. unattended nocturnal polygraphy under NIV (cf details below) will be performed at home with SomnoHolter® (Nomics, Liege, Belgium), synchronized with transcutaneous partial pressure in CO2 (PtcCO2) monitoring by SenTec V-Sign™ System.~The PtcCO2 device will be calibrated before and at the end of each night to allow drift correction.
Study NCT02409173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive positive airway pressure flow generator device
Description: Noninvasive positive airway pressure flow generator device.
Study NCT02409173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Description: Standard Roux-en-Y gastric bypass
Study NCT02570490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium fusidate
Study NCT02570490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid
Study NCT04482647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: View instructional video
Study NCT04482647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Perform meditation
Study NCT04482647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04482647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04482647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Perform breathing techniques
Study NCT02198027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of 0.25 % Bupivacaine into renal capsule to skin.
Study NCT02198027 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infiltration
Description: 23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of normal saline into renal capsule to skin
Study NCT03156049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sphenopalatine block
Description: patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
Study NCT03156049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greater occipital nerve block
Description: patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
Study NCT02245152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS
Description: A monthly dose of LNS (31 sachets of 20g) will be distributed to mothers attending well-baby visits and participating in small group counseling
Study NCT02245152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child's health and nutrition topics
Description: After the well-baby visit. Caregivers will be invited to participate in a small group counseling or BCC (2-3 caregivers at a time).~Every month a set of topics related to child's health and nutrition will be treated. These BCC sessions will be organized in an interactive way centering around the condition of the participating children.
Study NCT02245152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: National policy well-baby visits
Study NCT02245152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National policy well-baby visits
Study NCT01479465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 400 mg/m\^2 administered via intravenous bolus and 2400 mg/m\^2 via intravenous infusion over 46 hours
Study NCT04154787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: Investigation of LNP023
Study NCT04154787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Comparison of rituximab dose
Study NCT01775228 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Support
Description: Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
Study NCT06670183 — intervention group
Intervention type: OTHER
Intervention: Dietary patterns
Description: Dietary patterns such as regular meat-eater, occasional meat-eater, pescatarian, and vegetarian; Mediterranean diet.
Study NCT06670183 — intervention group
Intervention type: OTHER
Intervention: Food groups and Nutrients
Description: Dietary components, such as oily fish, dairy product, supplements, fibre, vitamin D supplements.
Study NCT06670183 — intervention group
Intervention type: OTHER
Intervention: Alcohol intake
Description: Frequency and intake of alcoholic beverages was measured by self-reporting the weekly frequency of different types of alcoholic beverages, e.g., the number of pints of beer/cider consumed per week and measures of spirits or liquors consumed per week were collected to assess consumption of beer/cider and spirits.
Study NCT06670183 — intervention group
Intervention type: OTHER
Intervention: Vitamin D status
Description: Serum 25(OH)D was measured once at baseline through a non-fasted blood draw during any season of the year.
Study NCT03800823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent group
Description: In group sessions parents will learn how to use positive parenting practices (e.g., encouragement and limit setting) instead of ineffective practices (e.g., coercive behaviour, negative reciprocity). Using a parent group approach, each of the 10 sessions consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments.
Study NCT03800823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth component
Description: After the group sessions, parents will receive a 6-month mHealth program (MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet/physical activity behaviours. The program includes information, advice, and strategies to change unhealthy behaviours and the possibility to register the child's intake of fruit, vegetables, candy, sweetened beverages, and sedentary time.
Study NCT03800823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care for overweight and obesity.
Study NCT02637206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 Cream
Description: GSK2894512 cream supplied will be white to off-white cream packaged in 28-gram laminate tubes of 2 concentrations: 0.5% and 1%, to be applied topically.
Study NCT02637206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Cream
Description: Vehicle Cream (placebo cream without active ingredient) supplied will be white to off-white cream packaged in 28-gram laminate tubes, to be applied topically.
Study NCT02637206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empty Patch
Description: Empty patches without any ingredients will be used as negative control.
Study NCT03497520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: asymmetric spinal stabilization exercise
Description: The patients were educated to strengthening weakness side of spinal muscle, as asymmetric spinal stabilization exercise(ASSE)~* before teach ASSE, the investigators will evaluate Cobb angle, Apical vertebral rotation in Adam's test, surface EMG, Scoliosis Research Society-22(SRS-22) quastionnaire for evaluation of scoliosis severity~* after perform ASSE, the investigators will evaluate Cobb angle, Apical vertebral rotation in Adam's test, surface EMG, Scoliosis Research Society-22(SRS-22) quastionnaire for evaluation of scoliosis severity
Study NCT03178318 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound
Description: ultrasound of the neck to identify the position of upper and lower border of the cricothyroid membrane.
Study NCT02146300 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1. session birch pollen nasal exposure 2. session xylometazoline nasal exposure
Description: Aquagen SQ 10 000 SQ/ml nasal exposure Xylometazoline 1 mg/ml nasal exposure
Study NCT01314638 — intervention group
Intervention type: OTHER
Intervention: Workshop balances
Description: one workshop per week for 20 weeks. Evaluation before and after.
Study NCT03925519 — intervention group
Intervention type: OTHER
Intervention: Supervised aerobic exercise
Study NCT04543942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol will be administered by IV infusion (60mg%).
Study NCT04543942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline is administered as the placebo
Study NCT02720978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Description: Intravenous oxytocin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery.
Study NCT02720978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal prostaglandin
Description: Vaginal prostaglandin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery.
Study NCT03404440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: L.Reuteri
Study NCT03404440 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: L.Reuteri
Study NCT03239353 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Entecavir
Description: Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.
Study NCT03239353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.
Study NCT03239353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir
Description: Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.
Study NCT02570971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Study NCT00926978 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radioactive Iodine 124
Description: After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is \< 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131.
Study NCT03437902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rutin in combination with Vitamin C
Description: Rutin and Vitamin C will be supplied as tablets containing 60 mg Rutin and 160 mg Vitamin C. The use of Rutin and Vitamin C will be under the trade name of RUTA C 60 ® manufactured by KAHIRA PHARM.\& CHEM. IND. Company
Study NCT03437902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C will be supplied as capsules containing500 mg of Vitamin C. The use of Vitamin C will be under the trade name of C-Retard ® manufactured by HIKMA Quality Company.
Study NCT02080117 — intervention group
Intervention type: PROCEDURE
Intervention: kidney transplantation, living or deceased donor
Study NCT03130699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dulce Digital
Description: One-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
Study NCT03130699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dulce Digital-Me (Automated Delivery)
Description: Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
Study NCT03130699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dulce Digital-Me (Medical Assistant)
Description: Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
Study NCT00859469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/m2 IV infusion for 2 hours
Study NCT00791765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept for subcutaneous injection.
Study NCT00791765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for subcutaneous injection.
Study NCT02754648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic ovarian endometriotic cyst
Study NCT01351285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: up-and-down method to find out effective concentration of remifentanil for preventing cough
Description: During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
Study NCT01351285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: up-and-down method to find out effective concentration of remifentanil for preventing cough
Description: During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
Study NCT04219033 — intervention group
Intervention type: OTHER
Intervention: EEG(Electroencephalogram) change
Description: patients are found to have characteristic EEG change
Study NCT02812706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution Route of administration: intravenous
Study NCT04370392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraperitoneal local anaesthetic instillation
Description: intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25) through the trocar at the subdiaphragmatic space in Trendelenburg's position for 5 min with intravenous infusion of 50 ml normal saline over 10 minutes.